← Back to patent-cliff list
NS-136
Tier C — Watch / tradeNS-136
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CHRM4
Indications (approved)：Schizophrenia, Alzheimer's disease
Regional status
US
Phase I
2024-05-08
EU
-
China
Phase II
2025-10-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NS-136?
Approved indications include: Schizophrenia, Alzheimer's disease.
When does the NS-136 patent expire?
No public expiry year is available for NS-136 yet; this page updates once verified.
How do I get a quote for NS-136 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30